BMS-986205
Sponsors
Bristol-Myers Squibb, Dana-Farber Cancer Institute
Conditions
Advanced CancerAdvanced Gastric CancerCancerHead and Neck CancerHealthyHealthy ParticipantsHealthy VolunteersLung Cancer
Phase 1
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
CompletedNCT02658890
Start: 2016-04-14End: 2021-10-26Updated: 2023-08-28
A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors
CompletedNCT03192943
Start: 2017-06-23End: 2018-12-11Updated: 2019-04-01
Pharmacokinetics and Metabolism Study in Healthy Male Participants
CompletedNCT03247283
Start: 2017-07-19End: 2017-10-15Updated: 2017-11-06
An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy Participants
CompletedNCT03312426
Start: 2017-10-09End: 2017-11-22Updated: 2018-01-19
A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects
CompletedNCT03346837
Start: 2017-11-22End: 2017-12-20Updated: 2018-02-28
A Study to Assess the Absorption of a Single Dose of BMS-986205 in Healthy Volunteers When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube, as Compared to a Tablet
CompletedNCT03362411
Start: 2017-11-09End: 2018-02-01Updated: 2018-02-23
A Study to Evaluate the Bioavailability of BMS-986205
CompletedNCT03374228
Start: 2018-01-04End: 2018-02-16Updated: 2018-06-28
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
CompletedNCT03459222
Start: 2018-05-30End: 2025-02-19Updated: 2025-04-02
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
CompletedNCT03792750
Start: 2018-12-31End: 2020-12-18Updated: 2022-02-28
A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy Participants
CompletedNCT03936374
Start: 2019-05-08End: 2019-07-20Updated: 2019-09-23
Phase 2
An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer
TerminatedNCT02750514
Start: 2016-05-09End: 2020-01-29Updated: 2021-03-22
A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer
CompletedNCT02935634
Start: 2016-11-29End: 2022-05-11Updated: 2023-06-09
A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
CompletedNCT02996110
Start: 2017-02-02End: 2021-11-23Updated: 2022-12-19
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
TerminatedNCT03519256
Start: 2018-08-02End: 2022-08-24Updated: 2023-06-01
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
WithdrawnNCT04007588
Start: 2019-09-06End: 2019-12-19Updated: 2020-02-05
Phase 3
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
CompletedNCT03329846
Start: 2017-11-30End: 2020-07-02Updated: 2021-07-09
An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
WithdrawnNCT03386838
Start: 2018-03-28End: 2018-04-19Updated: 2019-04-18
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
WithdrawnNCT03417037
Start: 2018-05-24End: 2025-08-20Updated: 2018-04-30